SurModics
SurModics provides proprietary hydrophilic and drug-delivery coatings, interventional thrombectomy devices (Pounce, Sublime), and IVD reagents (BioFX substrates, MatrixGuard diluent) to medical device OEMs, IVD developers, and hospitals, with manufacturing in Minnesota and Ireland.
- Company typePublic
- Founded1979
- HeadquartersEden Prairie, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What SurModics does
SurModics, Inc. (NASDAQ: SRDX prior to acquisition; legally Surmodics, Inc., domiciled in Minnesota) is a medical device coatings and in vitro diagnostics company founded in 1979 and headquartered in Eden Prairie, Minnesota with a second manufacturing facility in Ballinasloe, Ireland. The company operates three product segments: (1) Performance Coatings — proprietary hydrophilic, hemocompatible, and drug-delivery coatings (Preside platform) licensed to medical device OEMs serving neurovascular, peripheral, and coronary markets; (2) Interventional Medical Devices — the Pounce arterial and Pounce Venous thrombectomy systems, the Sublime Radial Access Platform, and the SurVeil drug-coated balloon for endovascular treatment of peripheral arterial and venous disease; and (3) In Vitro Diagnostics — BioFX TMB substrates, MatrixGuard diluent, protein stabilizers, blocking buffers, stop solutions, microarray slides, and antigens/antibodies (via DIARECT partnership) sold through shop.surmodics.com and international distributors. The company also operates a Contract Development & Manufacturing (CDMO) business providing end-to-end development and scalable manufacturing of complex medical devices for OEM partners.
Revenue mechanics combine OEM licensing/royalty streams (coatings), direct hardware sales (interventional devices), catalog-priced reagent sales (IVD e-commerce with unit prices ranging from $20 to $355), and professional services revenue (CDMO). The coatings and CDMO segments follow an enterprise sales-led motion with long qualification cycles tied to ISO 13485:2016 and ISO 9001:2015 certified manufacturing; IVD reagents are sold via a transactional e-commerce and distributor model; interventional devices are sold through a direct sales team to hospitals and medical facilities. SurModics holds a 40+ year IVD reagent track record with documented lot-to-lot consistency below 5% variation.
In May 2024, GTCR LLC announced a take-private acquisition of SurModics for approximately $627 million; the FTC's challenge was denied by the US District Court for the Northern District of Illinois in November 2025. Subsequently, the Pounce Thrombectomy System was divested to Endologix (closing May 18, 2026), and SurModics entered a merger/divestiture arrangement with Biocoat forming the SurModics Services & Technologies division (December 2025). The company maintains reported headcount of 251–500 employees and reported revenue in the approximately $126M range in FY2024.
SurModics firmographics
Firmographics- Name
- SurModics
- Legal name
- Surmodics, Inc.
- Website
- https://surmodics.com
- Company type
- Public
- Founded year
- 1979
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- SurModics provides proprietary hydrophilic and drug-delivery coatings, interventional thrombectomy devices (Pounce, Sublime), and IVD reagents (BioFX substrates, MatrixGuard diluent) to medical device OEMs, IVD developers, and hospitals, with manufacturing in Minnesota and Ireland.
- Ownership category
- akta.pro rank
SurModics industry classification
Industry- Product category
- Medical Device Coatings and In Vitro Diagnostics
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
- akta.pro secondary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
Keywords
Where SurModics is headquartered
LocationHeadquarters
- HQ city
- Eden Prairie
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
SurModics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Performance Coatings: Global leader in customized hydrophilic, hemocompatible, and drug-delivery coatings for intravascular medical devices. Serves neurovascular, peripheral, and coronary markets.
- Interventional Medical Devices: Manufactures and sells medical devices including Pounce Thrombectomy System, Pounce Venous Thrombectomy System, and Sublime Radial Access Platform for endovascular treatment of peripheral arterial and venous disease.
- In Vitro Diagnostics Products: Sells chemical components for IVD immunoassay tests and microarrays including TMB substrates, protein stabilizers, diluents, stop solutions, and microarray surfaces through e-commerce platform.
- Contract Development & Manufacturing (CDMO): Provides end-to-end development and scalable manufacturing of complex medical devices for OEM partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | 450 nm Stop Reagent for TMB Microwell Substrates (STPR) |
| Unit Pricing | Pay-as-you-go | Assay Diluent (Protein-Free) (SM01) |
| Unit Pricing | Pay-as-you-go | MatrixGuard Diluent (SM02) |
| Unit Pricing | Pay-as-you-go | TMB Super Sensitive One Component HRP Microwell Substrate (TMBS) |
| Unit Pricing | Pay-as-you-go | TMB Slow Kinetic One Component HRP Microwell Substrate (TMSK) |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
SurModics product offering
Product offeringCore offering
SurModics develops, manufactures, and sells surface modification coatings (hydrophilic, hemocompatible, drug-delivery) applied to intravascular medical devices, mechanical thrombectomy systems and radial access devices for endovascular treatment of peripheral arterial and venous disease, and chemical components (TMB substrates, protein stabilizers, diluents, blockers, microarray surfaces, antigens and antibodies) for in vitro diagnostic immunoassays. The company additionally provides end-to-end contract development and manufacturing (CDMO) services for complex medical device OEMs.
Product overview
SurModics provides a diversified portfolio of medical device coatings, in vitro diagnostic (IVD) products, and interventional medical devices. The company operates through three main segments: (1) Interventional Products including the Pounce™ Thrombectomy System (arterial, 2-10mm vessels), Pounce™ Venous Thrombectomy System (venous, 6-16mm vessels), Sublime™ Radial Access Platform, and Drug-Coated Balloons; (2) Performance Coatings featuring Preside™ Hydrophilic Coatings for neurovascular, coronary, and peripheral procedures; and (3) IVD Products including ELISA reagents (protein stabilizers, diluents, blockers, TMB substrates and stop solutions), microarray slides/surfaces, and antigens/antibodies through the DIARECT partnership. The company also offers Contract Development & Manufacturing (CDMO) services for complex medical devices.
Differentiator
Problem solved
Functional benefit
Brands
- Pounce™ Thrombectomy Platform: A mechanical thrombectomy system for non-surgical removal of peripheral arterial thrombi and emboli, with combined vessel diameter range of 2-10mm.
- Pounce™ Venous Thrombectomy System
- Sublime™ Radial Access Platform
- SurVeil™
- Preside™ Hydrophilic Coatings
- BioFX™
- MatrixGuard™ Diluent
Products and services
- Pounce Thrombectomy System
Quantifiable outcome
- High procedural success demonstrated in PROWL registry with 160 patients treated for real-world limb ischemia presentations
- +1 more outcomes
Companies that use SurModics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
SurModics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
SurModics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- EndologixcoreEndologix acquired the Pounce Thrombectomy System from SurModics, expanding its vascular intervention portfolio with the FDA-cleared mechanical thrombectomy platform. The transaction closed on May 18, 2026. A core group of SurModics employees supporting the Pounce platform transitioned to Endologix.
- BiocoatminorBiocoat announced formation of SurModics Services & Technologies division following merger and divestiture transactions. The division continues legacy operations after merging with SurModics and divesting certain assets, based in Horsham, Pennsylvania, providing advanced coating solutions and services to medical device manufacturers globally.
- Vetax MedicalminorSurModics acquired Vetax Medical for $39.9 million to expand its thrombectomy product line. The acquisition added the FDA 510(k)-cleared ReVene Thrombectomy Catheter designed for venous clot removal to SurModics' portfolio.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
SurModics competitors and assessment
Company assessmentDirect peers
- AngioDynamics: AngioDynamics offers peripheral vascular intervention products including the AlphaVac mechanical thrombectomy system, directly competing with SurModics' interventional portfolio in the peripheral thrombectomy and vascular access market.
- DSM Biomedical (dsm-firmenich): DSM Biomedical provides biomedical materials including hydrophilic coatings and surface modification technologies for medical devices, directly competing with SurModics' Preside Hydrophilic Coatings and performance coatings portfolio.
- Penumbra: Penumbra develops mechanical thrombectomy systems (Indigo aspiration system) for peripheral and neurovascular applications, directly competing with SurModics' Pounce Thrombectomy Platform in the mechanical clot-removal category.
- Inari Medical: Inari Medical (acquired by Stryker in 2024) offers FlowTriever and ClotTriever systems for venous thromboembolism, directly competing with SurModics' Pounce Venous Thrombectomy System in the venous clot-removal market.
- Biocoat: Biocoat is a direct competitor in hydrophilic coatings for medical devices and entered into a structural transaction with SurModics in December 2025, suggesting close competitive overlap in the coatings and CDMO space.
- Integer Holdings: Integer Holdings is a leading medical device contract design and manufacturing organization (CDMO), directly comparable to SurModics' Contract Development & Manufacturing services for complex medical devices.
- Harland Medical Systems: Harland Medical Systems specializes in medical device coatings including hydrophilic and hemocompatible coatings, directly competing with SurModics' Preside Hydrophilic Coatings and broader performance coatings business.
- Bio-Rad Laboratories: Bio-Rad Laboratories is a major manufacturer of IVD reagents, immunoassay components, and diagnostic test kits, directly comparable to SurModics' BioFX TMB substrates, MatrixGuard diluents, and broader IVD reagent offerings.
Broad incumbents
- Boston Scientific: Boston Scientific is a large diversified medical device company with peripheral intervention, vascular, and drug-delivery coating products, representing a broader incumbent competitor to SurModics across multiple segments including coatings and interventional devices.
- Merit Medical Systems: Merit Medical is a broader incumbent in peripheral vascular and interventional devices, including catheters and clot management products, with overlapping capabilities to SurModics' Sublime Radial Access Platform and peripheral intervention portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks4 records
Key highlights5 records
Customer concentration
SurModics social profiles
Digital presenceSurModics compliance and trust
Trust signalCompliance2 records
SurModics financial estimates
Financial estimateRevenue estimate
Valuation estimate
SurModics leadership team
Management profileNumber of profiles
Profiles4 records
SurModics subsidiaries and ownership
Company hierarchySubsidiaries1 record
SurModics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SurModics M&A and investment
M&A and investmentM&A6 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SurModics
What does SurModics do?
SurModics develops, manufactures, and sells surface modification coatings (hydrophilic, hemocompatible, drug-delivery) applied to intravascular medical devices, mechanical thrombectomy systems and radial access devices for endovascular treatment of peripheral arterial and venous disease, and chemical components (TMB substrates, protein stabilizers, diluents, blockers, microarray surfaces, antigens and antibodies) for in vitro diagnostic immunoassays. The company additionally provides end-to-end contract development and manufacturing (CDMO) services for complex medical device OEMs.
Is SurModics a public or private company?
SurModics is a public company. It is classified as private equity controlled and is currently operating.
When was SurModics founded?
SurModics was founded in 1979. It employs 251 to 500 people.
Where is SurModics based?
SurModics is headquartered in Eden Prairie, United States, in the North America region.
How does SurModics make money?
Four revenue lines are on record. Performance Coatings are the primary driver. The others are interventional Medical Devices, in Vitro Diagnostics Products and contract Development & Manufacturing (CDMO).
Who are SurModics's main competitors?
Direct peers on record are AngioDynamics, DSM Biomedical (dsm-firmenich), Penumbra, Inari Medical, Biocoat, Integer Holdings, Harland Medical Systems and Bio-Rad Laboratories. Broad incumbents are Boston Scientific and Merit Medical Systems.
Does SurModics have an API?
No public API is recorded for SurModics.
What industry is SurModics in?
SurModics's product category is Medical Device Coatings and In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 339113 and its SIC code is 3841.